Lantheus Q2 Beats Across the Board, But Suspends Guidance Amid $8B Curium Buyout
LNTH has more than doubled off its 52-week low of $47.25.
Summary
Lantheus delivered a strong Q2, with revenue of $388.2M beating consensus by over $25M and adjusted EPS of $1.55 topping estimates by $0.25. The beat was driven by DEFINITY growth of 5.2%, offsetting a 4.1% decline in PYLARIFY and the complete loss of SPECT revenue. However, the company suspended its full-year 2026 guidance, citing the pending acquisition by Curium. This follows the definitive merger agreement announced on August 3, which values Lantheus at up to $8B or $114.50 per share including CVRs. The earnings beat reinforces the standalone value, but the guidance suspension underscores that the merger is the dominant narrative. With the stock trading near the $102.50 upfront offer, the results are unlikely to shift the deal calculus materially, but they remove a potential overhang ahead of the shareholder vote.
At the time of this announcement, LNTH was trading at $101.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $47.25 to $111.86. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.